BSF Enterprise Plc

BSFA

GB00BHNBDQ51

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:08 2024-07-16 EDT			5-day change	1st Jan Change
4.25 ^GBX	-5.56%		-10.53%	-58.54%

06-11	BSF agreements with leading brands validates market potential says CEO	AN
06-11	Earnings Flash (BSFA.L) BSF ENTERPRISE Posts Fiscal H1 Revenue GBP54,295	MT

BSF Enterprise Plc Reports Earnings Results for the Full Year Ended September 30, 2022

January 31, 2023 at 11:37 am

BSF Enterprise Plc reported earnings results for the full year ended September 30, 2022. For the full year, the company reported net loss was GBP 0.930039 million compared to GBP 0.058325 million a year ago. Basic loss per share from continuing operations was GBP 0.0206 compared to GBP 0.0029 a year ago.

Latest news about BSF Enterprise Plc

BSF agreements with leading brands validates market potential says CEO	06-11	AN
Earnings Flash (BSFA.L) BSF ENTERPRISE Posts Fiscal H1 Revenue GBP54,295	06-11	MT
Earnings Flash (BSFA.L) BSF ENTERPRISE Reports Fiscal H1 Loss GBX-0.84	06-11	MT
BSF Enterprise Plc Reports Earnings Results for the Half Year Ended March 31, 2024	06-11	CI
BSF Enterprise Plc announced that it has received £0.09 million in funding	04-11	CI
BSF Enterprise Gets Funding for Development of Cultivated Leather	04-11	MT
BSF Enterprise makes progress across its alternative leather project	04-11	AN
BSF Enterprise Wins £38,000 in Grant Funding from the Government Agency Innovate UK to Begin Its Project with the University of Northampton	04-11	CI
BSF subsidiaries get grant funding to partner with UK universities	03-20	AN
BSF Enterprise shares up as strikes collaboration pact with Ivy Farm	03-07	AN
United Oil adds Jamaica expert; Vaalco makes buy	02-29	AN
BSF Enterprise PLC Announces MoU with Amelie Pichard to Produce Fashion Accessory Using Lab-Grown Leather	02-29	CI
BSF Enterprise to set up seperate lab-grown leather subsidiary	02-15	AN
BSF Enterprise to Create New Subsidiary for Leather Business	02-15	MT
EARNINGS: BSF Enterprise "making great strides", Sylvania ups earnings	01-31	AN
Earnings Flash (BSFA.L) BSF ENTERPRISE Posts FY23 Loss GBX-1.59	01-31	MT
BSF Enterprise Plc Reports Earnings Results for the Full Year Ended September 30, 2023	01-31	CI
At least 3 killed, 12 injured in unrest in India's Manipur state	01-02	RE
BSF Enterprise forms cultivated meat JV with CellulaRevolution	12-08	AN
BSF Enterprise, CellulaRevolution to Form New Food Technology Company	12-08	MT
BSF Enterprise Plc Announces Foodtech Joint Venture with CellulaREvolution Limited	12-08	CI
BSF Enterprise's 3D Bio-Tissues inks deal to test Etsyl in cosmetics	11-24	AN
BSF Enterprise Unit Mulls Possible Collaboration with Cosmetic Company	11-24	MT
BSF Enterprise Forms New Lab-Grown Cornea Company	23-10-26	MT
Anglo Asian to restart Gedabek operations on approval	23-09-26	AN

Chart BSF Enterprise Plc

Duration

Period

More charts

Company Profile

BSF Enterprise PLC is a United Kingdom-based biotechnology company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. 3DBT has three strands of three intellectual property (IP) each with a different sector focus development and revenue timeline. 3DBTâs City-mix is an animal-free cell growth agent for culturing skin, muscle and fat cells which are used for lab-grown meat and leather production. 3DBTâs Lipopeptide Etsyl actively increases collagen production in human skin cells which can be used in cosmetic and skin care products.

Sector

Pharmaceuticals

Calendar

2025-01-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
BSF ENTERPRISE PLC	-58.54%	6.04M
CSL LIMITED	+7.40%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.18B
BIOGEN INC.	-13.04%	32.26B
UCB	+80.80%	29.79B
BIOMARIN PHARMACEUTICAL INC.	-10.92%	16.06B
INCYTE CORPORATION	+1.93%	14.45B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.01B
ALTEOGEN INC.	+177.16%	10.71B
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	8.89B